TUCSON, AZ — March 30, 2026 — BioXgen, the medical device company developing the first cardiac patch specifically designed to prevent post-operative atrial fibrillation (POAF), has opened a Community Investment Round under Regulation Crowdfunding (Reg CF).  POAF is the number-one complication following open-heart surgery. Roughly 50 percent of the 500,000 Americans who undergo open-heart surgery each year develop the arrhythmia within four days of leaving the operating room. It raises the risk of stroke, recurrent atrial fibrillation, kidney failure, and death. No FDA-cleared device exists to prevent it. Surgeons have managed this problem with off-label pharmaceuticals for decades. Nothing has moved the needle. The cost to the U.S. healthcare system runs approximately $9 billion annually. BioXgen's cardiac patch is placed directly on the surface of the heart during surgery. Pre-clinical data shows that POAF rates dropped from about 50% to under 5 percent — a 10-fold reduction. The data are published in Circulation (Rao et al. / Konhilas, v.136, 2017). In unpublished data, over 200 additional patients have been treated with similar results. The Q-submission to the FDA is complete, solidifying the 510(k) pathway. A Clear Regulatory Path BioXgen is pursuing FDA clearance through the 510(k) pathway, which establishes substantial equivalency to materials already cleared by the agency. Total development time to clearance is targeted at under 18 months if we meet critical funding needs. The device will be ready for use in patients as soon as the 510(k) approval is secured.  Target: standard of care within 36 to 48 months. The Investment Structure The offering is structured as a Regulation Crowdfunding (RegCF) and hosted by DealMaker Securities. Investments start at $500, allowing retail investors to participate in a category that has historically been reserved for institutional capital. BioXgen is built lean — contracted manufacturing, a growing IP portfolio, and a cap table specifically designed to accommodate community investors alongside institutional partners. The Founders Dr. David Skinner (MD, PhD, MBA) serves as President and CEO. He built a medical company from five hand-picked employees to 156 across nine locations in three years, then exited at 10x. His MD/PhD from the University of Arizona was completed in five years with the Outstanding Achievement Award. He holds an MBA from the W.P. Carey School of Business with a focus in finance. Dr. John P. Konhilas (PhD) serves as Chief Science Officer. He spent more than 30 years as a professor of physiology at the University of Arizona, where he studied cardiac disease and therapeutic development. Fifteen of those years focused on how biological scaffolds affect clinical outcomes after open-heart surgery. He holds 11 patents with multiple provisionals pending, has direct experience with 510(k), IND, BLA, and NDA pathways, and co-founded Menolabs, which was acquired in 2022. Live Investor Presentation — April 7 Dr. Skinner and Dr. Konhilas will present the full 2026 Community Investment Round pitch deck live and take direct questions from prospective investors. Monday, April 7, 2025 | 1:30 PM PT Zoom Webinar | Free | Registration Required Register: https://dnagency.lpages.co/bioxgen-investor-presentation/  "We have the data, the regulatory path, the clinical partner, and the team that has done this before," said Dr. Skinner. "This round lets people outside the institutional world participate in a device that solves a real problem." To view the offering and invest: https://invest.bioxgen.life/    Disclaimer: In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. BioXgen has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained here: https://invest.bioxgen.life/